The Advanced Drug Delivery and Biomaterials (ADDB) group develops new therapies for neurological diseases, and more particularly for spinal cord injury and multiple sclerosis. Their research focuses on 2 main axes: 1) drug delivery for the central nervous system and 2) tissue engineering and regenerative medicine. The ADDB group, in collaboration with several local and international teams, develops strategies to stimulate tissue repair using novel nanomedicines and stem cell delivery systems that combine hydrogels, MSC, and nanomedicines. Lately, they have been working on extracellular vesicles and their use as drug delivery systems, and are developing a microfluidics platform for the production of nano- and micro-particles for the delivery of bioactive particles and cells.